Zoetis (NYSE:ZTS) Shares Unloaded Rep. Rick Larsen

Key Points

• Representative Rick Larsen sold shares of Zoetis Inc. ranging between $1,001 and $15,000 on October 6th, as disclosed on October 16th.
• Zoetis reported a quarterly earnings of $1.76 per share, exceeding estimates, with revenue of $2.46 billion, marking a 4.2% increase from the previous year.
• The company recently announced a quarterly dividend of $0.50 per share, with a yield of 1.4%, expected to be paid on December 2nd.

Representative Rick Larsen (D-Washington) recently sold shares of Zoetis Inc. NYSE: ZTS. In a filing disclosed on October 16th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on October 6th. The trade occurred in the Representative's "RICHARD R LARSEN IRA" account.

Representative Rick Larsen also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Walmart NYSE: WMT on 10/6/2025.
• Purchased $1,001 - $15,000 in shares of American Electric Power NASDAQ: AEP on 10/6/2025.
• Sold $1,001 - $15,000 in shares of Colgate-Palmolive NYSE: CL on 10/6/2025.
• Sold $1,001 - $15,000 in shares of Old Dominion Freight Line NASDAQ: ODFL on 10/6/2025.
• Purchased $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 10/6/2025.

Zoetis Trading Up 0.6%

Zoetis stock opened at $144.15 on Friday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $193.49. The company has a market capitalization of $63.88 billion, a price-to-earnings ratio of 24.81, a price-to-earnings-growth ratio of 2.30 and a beta of 0.90. The business's fifty day simple moving average is $148.73 and its two-hundred day simple moving average is $153.76. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis's payout ratio is presently 34.42%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ZTS. Argus reaffirmed a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings restated a "hold (c-)" rating on shares of Zoetis in a report on Wednesday, October 8th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $196.71.

Institutional Trading of Zoetis

A number of hedge funds have recently bought and sold shares of ZTS. Nova Wealth Management Inc. bought a new stake in shares of Zoetis during the 1st quarter valued at about $25,000. Halbert Hargrove Global Advisors LLC boosted its holdings in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock worth $25,000 after buying an additional 144 shares during the last quarter. 1248 Management LLC bought a new stake in Zoetis during the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new stake in Zoetis during the first quarter valued at approximately $29,000. Finally, Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

About Representative Larsen

Rick Larsen (Democratic Party) is a member of the U.S. House, representing Washington's 2nd Congressional District. He assumed office on January 3, 2001. His current term ends on January 3, 2027. Larsen (Democratic Party) is running for re-election to the U.S. House to represent Washington's 2nd Congressional District. He declared candidacy for the 2026 election. Since at least 2011, Larsen has been assigned to the Committee on Armed Services and the Committee on Transportation and Infrastructure. Larsen's first position as an elected official was in 1998 as a member of the Snohomish County Council. Larsen earned his bachelor's degree from Pacific Lutheran University. After earning his master's degree in public affairs from the University of Minnesota, Larsen worked as the director of public affairs for the Washington State Dental Association and then as an economic development official with the Port of Everett. He went on to serve on the Snohomish County Council before seeking election to the U.S. House.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.